Spliceosomal dysregulation may switch FGFR2b to FGFR2c, altering ligand binding and driving dedifferentiation [159] or EMT [160], e.g., during progression of hormone-dependent to -resistant cancers [161, 162], or associated with constitutive EGFR activation in HPV16 E5-induced neoplasia [163]. Here, EGFR is linked to neoplasm.